The Navigation Model of Therapy: Why Awareness Changes Everything
November 16, 2025
Brand Name :
Synonyms :
Class :
4 - 8
mg
Orally 
4 times a day
Dose Adjustments
6mg- 12mg orally two times a day (extended-release)
The dose may vary depending on the patient's response.
In most patients, the dose is maybe once a day at bedtime
Maximum dose: 24mg/day
4 - 8
mg
Orally 
Dose Adjustments
The dose may vary depending on the patient's response.
In most patients, the dose may be two times a day
6mg- 12mg orally two times a day (extended-release)
The dose may vary depending on the patient's response.
In most patients, the dose is maybe once a day at bedtime
Maximum dose: 24mg/day
The dose may vary depending on the patient's response.
In most patients, the dose may be two times a day
6mg- 12mg orally two times a day (extended-release)
The dose may vary depending on the patient's response.
In most patients, the dose is maybe once a day at bedtime
Maximum dose: 24mg/day:
4 - 8
mg
Orally 
4 times a day
5 - 20
mg
Subcutaneous (SC)
two to four times a day
5mg- 20mg, SC/IV/IM two to four times a day
Maximum dose: 40mg/day (parenteral)
For children less than six years old:
0.125mg/kg four times a day (immediate release)
Maximum dose: 6mg- 8mg/day
2mg suspension (extended-release) orally two times a day
Note: do not administer more than two doses per day
For children of 6- 12 years of age:
2mg- 4mg orally 3-4 times a day (immediate release)
Maximum dose: 12-16mg/day
4mg suspension orally (extended-release), two times a day
Note: Do not exceed two doses per day
For children more than 12 years of age:
4mg- 8mg orally four times a day (immediate release)
The dose may vary depending on the patient's response.
In most patients, the dose may be two times a day
6mg- 12mg orally two times a day (extended-release)
The dose may vary depending on the patient's response.
In most patients, the dose is maybe once a day at bedtime
Maximum dose: 24mg/day
For children less than six years old:
0.125mg/kg four times a day (immediate release)
Maximum dose: 6mg- 8mg/day
2mg suspension (extended-release) orally two times a day
Note: do not administer more than two doses per day
For children of 6- 12 years of age:
2mg- 4mg orally 3-4 times a day (immediate release)
Maximum dose: 12-16mg/day
4mg suspension orally (extended-release), two times a day
Note: Do not exceed two doses per day
For children more than 12 years of age:
4mg- 8mg orally four times a day (immediate release)
The dose may vary depending on the patient's response.
In most patients, the dose may be two times a day
6mg- 12mg orally two times a day (extended-release)
The dose may vary depending on the patient's response.
In most patients, the dose is maybe once a day at bedtime
Maximum dose: 24mg/day
For children less than six years old:
0.125mg/kg four times a day (immediate release)
Maximum dose: 6mg- 8mg/day
2mg suspension (extended-release) orally two times a day
Note: do not administer more than two doses per day
For children of 6- 12 years of age:
2mg- 4mg orally 3-4 times a day (immediate release)
Maximum dose: 12-16mg/day
4mg suspension orally (extended-release), two times a day
Note: Do not exceed two doses per day
For children more than 12 years of age:
4mg- 8mg orally four times a day (immediate release)
The dose may vary depending on the patient's response.
In most patients, the dose may be two times a day
6mg- 12mg orally two times a day (extended-release)
The dose may vary depending on the patient's response.
In most patients, the dose is maybe once a day at bedtime
Maximum dose: 24mg/day
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may have an increased risk of adverse effects when combined with tropicamide
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
calcium, magnesium, potassium and sodium oxybateÂ
The effect of either of the drugs is increased due to pharmacodynamic synergism. May result in respiratory depression, coma, or death
The effect of either of the drugs is increased due to pharmacodynamic synergism.
The activity of brompheniramine may be increased
The effect of either of the drugs is increased
an increase in sedation may be seen when coadministered
the effect of pitolisant may be reduced
The effect of either of the drugs is increased due to pharmacodynamic synergism.
the effect of brompheniramine may be increased
It may enhance sedation when combined with tramadol
When metixene and brompheniramine are combined, the risk or seriousness of adverse events will rise
The potential for increased CNS depression risk or seriousness occurs when brompheniramine is used together with pinazepam
when ajmaline is used together with brompheniramine, the risk or seriousness of QTc prolongation is enhanced
The potential for increased CNS depression risk or seriousness occurs when brompheniramine is used together with pipecuronium
When brompheniramine is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
When captodiame is used together with brompheniramine, There is a risk or seriousness of CNS depression is enhanced
When brompheniramine is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when brompheniramine is used together with fencamfamin
When brompheniramine is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When brompheniramine is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When chlordiazepoxide is used together with brompheniramine, this leads to enhanced risk or seriousness of CNS depression
When brompheniramine is used together with melitracen, this leads to enhanced risk or seriousness of CNS depression
When ponesimod is used together with brompheniramine, this leads to enhanced risk or seriousness of bradycardia
When brompheniramine is used together with adenosine, this leads to enhanced risk or seriousness of QTc prolongation
When brompheniramine is used together with givinostat, this leads to enhanced risk or seriousness of Qtc prolongation
When emylcamate is used together with brompheniramine, this leads to enhanced risk or seriousness of CNS depression
When brompheniramine is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with brompheniramine, this leads to enhanced risk or seriousness of CNS depression
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
may increase the efficacy of each other when combined
an increase in sedation can be seen if coadministered
an increase in sedation can be seen if coadministered
the toxic effects of amifampridine may be increased
an increase in sedation can be seen if coadministered
an increase in sedation can be seen if coadministered
an increase in sedation can be seen if coadministered
an increase in sedation can be seen if coadministered
When brompheniramine is used together with profenamine, this leads to enhanced risk or seriousness of adverse events
brompheniramine: it may increase the metabolism of cerivastatin
when combined, it may increase sedation
when combined, it may increase sedation
may increase the effects of pharmacodynamic synergism
an increase in severity of adverse effects can be seen when brompheniramine is administered with agmatine